STAT3 signaling in immunity

Cytokine and Growth Factor Reviews

Volumn 31, Issue , 2016, Pages 1-15

  Hillmer, Emily J ^a   Zhang, Huiyuan ^a   Li, Haiyan S ^a   Watowich, Stephanie S ^a,b  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^b UNIVERSITY OF TEXAS   (United States)

Author keywords

Cytokines; Immune system; Inflammation; STAT3

Indexed keywords

CHEMOKINE RECEPTOR CXCR5; INTERLEUKIN 21; INTERLEUKIN 6; STAT3 PROTEIN;

ADAPTIVE IMMUNITY; AUTOIMMUNITY; B LYMPHOCYTE; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CYTOKINE PRODUCTION; CYTOKINE RELEASE; DENDRITIC CELL; GENE; GENE DELETION; GENE INACTIVATION; GENE MUTATION; GRANULOPOIESIS; HUMAN; HYPER IMMUNOGLOBULIN E SYNDROME; IMMUNE DEFICIENCY; IMMUNITY; IMMUNOPATHOLOGY; INNATE IMMUNITY; INTRACELLULAR SIGNALING; NONHUMAN; PHAGOCYTE; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN STRUCTURE; REVIEW; STAT3 GENE; STEADY STATE; STRUCTURE ACTIVITY RELATION; ANIMAL; GENETICS; IMMUNOLOGY; MUTATION;

ADAPTIVE IMMUNITY; ANIMALS; HUMANS; IMMUNE SYSTEM DISEASES; IMMUNITY, INNATE; MUTATION; STAT3 TRANSCRIPTION FACTOR;

EID: 84966551223     PISSN: 13596101     EISSN: 18790305     Source Type: Journal    
DOI: 10.1016/j.cytogfr.2016.05.001     Document Type: Review

References (225)

1. [1] Lutticken, C., Wegenka, U.M., Yuan, J., Buschmann, J., Schindler, C., Ziemiecki, A., et al. Association of transcription factor APRF and protein kinase Jak1 with the interleukin-6 signal transducer gp130. Science 263 (1994), 89–92.
2. [2] Standke, G.J., Meier, V.S., Groner, B., Mammary gland factor activated by prolactin on mammary epithelial cells and acute-phase response factor activated by interleukin-6 in liver cells share DNA binding and transactivation potential. Mol. Endocrinol. 8 (1994), 469–477.
3. [3] Zhong, Z., Wen, Z., Darnell, J.E. Jr., Stat3: a STAT family member activated by tyrosine phosphorylation in response to epidermal growth factor and interleukin-6. Science 264 (1994), 95–98.
4. [4] Wegenka, U.M., Lutticken, C., Buschmann, J., Yuan, J., Lottspeich, F., Muller-Esterl, W., et al. The interleukin-6-activated acute-phase response factor is antigenically and functionally related to members of the signal transducer and activator of transcription (STAT) family. Mol. Cell. Biol. 14 (1994), 3186–3196.
5. [5] Akira, S., Nishio, Y., Inoue, M., Wang, X.J., Wei, S., Matsusaka, T., et al. Molecular cloning of APRF, a novel IFN-stimulated gene factor 3 p91-related transcription factor involved in the gp130-mediated signaling pathway. Cell 77 (1994), 63–71.
6. [6] Raz, R., Durbin, J.E., Levy, D.E., Acute phase response factor and additional members of the interferon-stimulated gene factor 3 family integrate diverse signals from cytokines, interferons, and growth factors. J. Biol. Chem. 269 (1994), 24391–24395.
7. [7] Ruff-Jamison, S., Zhong, Z., Wen, Z., Chen, K., Darnell, J.E. Jr., Cohen, S., Epidermal growth factor and lipopolysaccharide activate Stat3 transcription factor in mouse liver. J. Biol. Chem. 269 (1994), 21933–21935.
8. [8] Tian, S.S., Lamb, P., Seidel, H.M., Stein, R.B., Rosen, J., Rapid activation of the STAT3 transcription factor by granulocyte colony-stimulating factor. Blood 84 (1994), 1760–1764.
9. [9] Yu, C.L., Meyer, D.J., Campbell, G.S., Larner, A.C., Carter-Su, C., Schwartz, J., et al. Enhanced DNA-binding activity of a Stat3-related protein in cells transformed by the Src oncoprotein. Science 269 (1995), 81–83.
10. [10] Bromberg, J.F., Horvath, C.M., Besser, D., Lathem, W.W., Darnell, J.E. Jr., Stat3 activation is required for cellular transformation by v-src. Mol. Cell. Biol. 18 (1998), 2553–2558.
11. [11] Ram, P.T., Horvath, C.M., Iyengar, R., Stat3-mediated transformation of NIH-3T3 cells by the constitutively active Q205L Galphao protein. Science 287 (2000), 142–144.
12. [12] Zhang, Y., Turkson, J., Carter-Su, C., Smithgall, T., Levitzki, A., Kraker, A., et al. Activation of Stat3 in v-Src-transformed fibroblasts requires cooperation of Jak1 kinase activity. J. Biol. Chem. 275 (2000), 24935–24944.
13. [13] Gough, D.J., Corlett, A., Schlessinger, K., Wegrzyn, J., Larner, A.C., Levy, D.E., Mitochondrial STAT3 supports Ras-dependent oncogenic transformation. Science 324 (2009), 1713–1716.
14. [14] Gough, D.J., Koetz, L., Levy, D.E., The MEK-ERK pathway is necessary for serine phosphorylation of mitochondrial STAT3 and Ras-mediated transformation. PLoS One, 8, 2013, e83395.
15. [15] Boulton, T.G., Zhong, Z., Wen, Z., Darnell, J.E. Jr., Stahl, N., Yancopoulos, G.D., STAT3 activation by cytokines utilizing gp130 and related transducers involves a secondary modification requiring an H7-sensitive kinase. Proc. Natl. Acad. Sci. U. S. A. 92 (1995), 6915–6919.
16. [16] Wen, Z., Zhong, Z., Darnell, J.E. Jr., Maximal activation of transcription by Stat1 and Stat3 requires both tyrosine and serine phosphorylation. Cell 82 (1995), 241–250.
17. [17] Shen, Y., Schlessinger, K., Zhu, X., Meffre, E., Quimby, F., Levy, D.E., et al. Essential role of STAT3 in postnatal survival and growth revealed by mice lacking STAT3 serine 727 phosphorylation. Mol. Cell. Biol. 24 (2004), 407–419.
18. [18] Wen, Z., Darnell, J.E. Jr., Mapping of Stat3 serine phosphorylation to a single residue (727) and evidence that serine phosphorylation has no influence on DNA binding of Stat1 and Stat3. Nucleic Acids Res. 25 (1997), 2062–2067.
19. [19] Shuai, K., Stark, G.R., Kerr, I.M., Darnell, J.E. Jr., A single phosphotyrosine residue of Stat91 required for gene activation by interferon-gamma. Science 261 (1993), 1744–1746.
20. [20] Shuai, K., Schindler, C., Prezioso, V.R., Darnell, J.E. Jr., Activation of transcription by IFN-gamma: tyrosine phosphorylation of a 91-kD DNA binding protein. Science 258 (1992), 1808–1812.
21. [21] Schindler, C., Shuai, K., Prezioso, V.R., Darnell, J.E. Jr., Interferon-dependent tyrosine phosphorylation of a latent cytoplasmic transcription factor. Science 257 (1992), 809–813.
22. [22] Becker, S., Groner, B., Muller, C.W., Three-dimensional structure of the Stat3beta homodimer bound to DNA. Nature 394 (1998), 145–151.
23. [23] Heim, M.H., Kerr, I.M., Stark, G.R., Darnell, J.E. Jr., Contribution of STAT SH2 groups to specific interferon signaling by the Jak-STAT pathway. Science 267 (1995), 1347–1349.
24. [24] Horvath, C.M., Wen, Z., Darnell, J.E. Jr., A STAT protein domain that determines DNA sequence recognition suggests a novel DNA-binding domain. Genes Dev. 9 (1995), 984–994.
25. [25] Shuai, K., Horvath, C.M., Huang, L.H., Qureshi, S.A., Cowburn, D., Darnell, J.E. Jr., Interferon activation of the transcription factor Stat91 involves dimerization through SH2-phosphotyrosyl peptide interactions. Cell 76 (1994), 821–828.
26. [26] Paulson, M., Pisharody, S., Pan, L., Guadagno, S., Mui, A.L., Levy, D.E., Stat protein transactivation domains recruit p300/CBP through widely divergent sequences. J. Biol. Chem. 274 (1999), 25343–25349.
27. [27] Vinkemeier, U., Moarefi, I., Darnell, J.E. Jr., Kuriyan, J., Structure of the amino-terminal protein interaction domain of STAT-4. Science 279 (1998), 1048–1052.
28. [28] Chen, X., Vinkemeier, U., Zhao, Y., Jeruzalmi, D., Darnell, J.E. Jr., Kuriyan, J., Crystal structure of a tyrosine phosphorylated STAT-1 dimer bound to DNA. Cell 93 (1998), 827–839.
29. [29] Zhang, T., Kee, W.H., Seow, K.T., Fung, W., Cao, X., The coiled-coil domain of Stat3 is essential for its SH2 domain-mediated receptor binding and subsequent activation induced by epidermal growth factor and interleukin-6. Mol. Cell. Biol. 20 (2000), 7132–7139.
30. [30] Ota, N., Brett, T.J., Murphy, T.L., Fremont, D.H., Murphy, K.M., N-domain-dependent nonphosphorylated STAT4 dimers required for cytokine-driven activation. Nat. Immunol. 5 (2004), 208–215.
31. [31] Hou, T., Ray, S., Lee, C., Brasier, A.R., The STAT3 NH2-terminal domain stabilizes enhanceosome assembly by interacting with the p300 bromodomain. J. Biol. Chem. 283 (2008), 30725–30734.
32. [32] Yuan, Z.L., Guan, Y.J., Chatterjee, D., Chin, Y.E., Stat3 dimerization regulated by reversible acetylation of a single lysine residue. Science 307 (2005), 269–273.
33. [33] Yang, J., Huang, J., Dasgupta, M., Sears, N., Miyagi, M., Wang, B., et al. Reversible methylation of promoter-bound STAT3 by histone-modifying enzymes. Proc. Natl. Acad. Sci. U. S. A. 107 (2010), 21499–21504.
34. [34] Dasgupta, M., Unal, H., Willard, B., Yang, J., Karnik, S.S., Stark, G.R., Critical role for lysine 685 in gene expression mediated by transcription factor unphosphorylated STAT3. J. Biol. Chem. 289 (2014), 30763–30771.
35. [35] Dasgupta, M., Dermawan, J.K., Willard, B., Stark, G.R., STAT3-driven transcription depends upon the dimethylation of K49 by EZH2. Proc. Natl. Acad. Sci. U. S. A. 112 (2015), 3985–3990.
36. [36] Bromberg, J.F., Wrzeszczynska, M.H., Devgan, G., Zhao, Y., Pestell, R.G., Albanese, C., et al. Stat3 as an oncogene. Cell 98 (1999), 295–303.
37. [37] Sadowski, H.B., Shuai, K., Darnell, J.E. Jr., Gilman, M.Z., A common nuclear signal transduction pathway activated by growth factor and cytokine receptors. Science 261 (1993), 1739–1744.
38. [38] Darnell, J.E. Jr., Kerr, I.M., Stark, G.R., Jak-STAT pathways and transcriptional activation in response to IFNs and other extracellular signaling proteins. Science 264 (1994), 1415–1421.
39. [39] Schindler, C., Darnell, J.E. Jr., Transcriptional responses to polypeptide ligands: the JAK-STAT pathway. Annu. Rev. Biochem. 64 (1995), 621–651.
40. [40] Darnell, J.E. Jr., STATs and gene regulation. Science 277 (1997), 1630–1635.
41. [41] Levy, D.E., Darnell, J.E. Jr., Stats: transcriptional control and biological impact. Nat. Rev. Mol. Cell. Biol. 3 (2002), 651–662.
42. [42] Stark, G.R., How cells respond to interferons revisited: from early history to current complexity. Cytokine Growth Factor Rev. 18 (2007), 419–423.
43. [43] Yang, J., Chatterjee-Kishore, M., Staugaitis, S.M., Nguyen, H., Schlessinger, K., Levy, D.E., et al. Novel roles of unphosphorylated STAT3 in oncogenesis and transcriptional regulation. Cancer Res. 65 (2005), 939–947.
44. [44] Yang, J., Liao, X., Agarwal, M.K., Barnes, L., Auron, P.E., Stark, G.R., Unphosphorylated STAT3 accumulates in response to IL-6 and activates transcription by binding to NFkappaB. Genes Dev. 21 (2007), 1396–1408.
45. [45] Yang, J., Stark, G.R., Roles of unphosphorylated STATs in signaling. Cell Res. 18 (2008), 443–451.
46. [46] Timofeeva, O.A., Chasovskikh, S., Lonskaya, I., Tarasova, N.I., Khavrutskii, L., Tarasov, S.G., et al. Mechanisms of unphosphorylated STAT3 transcription factor binding to DNA. J. Biol. Chem. 287 (2012), 14192–14200.
47. [47] Narimatsu, M., Maeda, H., Itoh, S., Atsumi, T., Ohtani, T., Nishida, K., et al. Tissue-specific autoregulation of the stat3 gene and its role in interleukin-6-induced survival signals in T cells. Mol. Cell. Biol. 21 (2001), 6615–6625.
48. [48] Wegrzyn, J., Potla, R., Chwae, Y.J., Sepuri, N.B., Zhang, Q., Koeck, T., et al. Function of mitochondrial Stat3 in cellular respiration. Science 323 (2009), 793–797.
49. [49] Garama, D.J., Harris, T.J., White, C.L., Rossello, F.J., Abdul-Hay, M., Gough, D.J., et al. A synthetic lethal interaction between glutathione synthesis and mitochondrial reactive oxygen species provides a tumor-specific vulnerability dependent on STAT3. Mol. Cell. Biol. 35 (2015), 3646–3656.
50. [50] Carbognin, E., Betto, R.M., Soriano, M.E., Smith, A.G., Martello, G., Stat3 promotes mitochondrial transcription and oxidative respiration during maintenance and induction of naive pluripotency. EMBO J. 35 (2016), 618–634.
51. [51] Lipinski, M.M., Hoffman, G., Ng, A., Zhou, W., Py, B.F., Hsu, E., et al. A genome-wide siRNA screen reveals multiple mTORC1 independent signaling pathways regulating autophagy under normal nutritional conditions. Dev. Cell 18 (2010), 1041–1052.
52. [52] Shen, S., Niso-Santano, M., Adjemian, S., Takehara, T., Malik, S.A., Minoux, H., et al. Cytoplasmic STAT3 represses autophagy by inhibiting PKR activity. Mol. Cell 48 (2012), 667–680.
53. [53] Niso-Santano, M., Shen, S., Adjemian, S., Malik, S.A., Marino, G., Lachkar, S., et al. Direct interaction between STAT3 and EIF2AK2 controls fatty acid-induced autophagy. Autophagy 9 (2013), 415–417.
54. [54] Der, C.J., Krontiris, T.G., Cooper, G.M., Transforming genes of human bladder and lung carcinoma cell lines are homologous to the ras genes of Harvey and Kirsten sarcoma viruses. Proc. Natl. Acad. Sci. U. S. A. 79 (1982), 3637–3640.
55. [55] Parada, L.F., Tabin, C.J., Shih, C., Weinberg, R.A., Human EJ bladder carcinoma oncogene is homologue of Harvey sarcoma virus ras gene. Nature 297 (1982), 474–478.
56. [56] Santos, E., Tronick, S.R., Aaronson, S.A., Pulciani, S., Barbacid, M., T24 human bladder carcinoma oncogene is an activated form of the normal human homologue of BALB- and Harvey-MSV transforming genes. Nature 298 (1982), 343–347.
57. [57] Corcoran, R.B., Contino, G., Deshpande, V., Tzatsos, A., Conrad, C., Benes, C.H., et al. STAT3 plays a critical role in KRAS-induced pancreatic tumorigenesis. Cancer Res. 71 (2011), 5020–5029.
58. [58] Gough, D.J., Marie, I.J., Lobry, C., Aifantis, I., Levy, D.E., STAT3 supports experimental K-RasG12D-induced murine myeloproliferative neoplasms dependent on serine phosphorylation. Blood 124 (2014), 2252–2261.
59. [59] Grabner, B., Schramek, D., Mueller, K.M., Moll, H.P., Svinka, J., Hoffmann, T., et al. Disruption of STAT3 signalling promotes KRAS-induced lung tumorigenesis. Nat. Commun., 6, 2015, 6285.
60. [60] Minegishi, Y., Saito, M., Morio, T., Watanabe, K., Agematsu, K., Tsuchiya, S., et al. Human tyrosine kinase 2 deficiency reveals its requisite roles in multiple cytokine signals involved in innate and acquired immunity. Immunity 25 (2006), 745–755.
61. [61] Zhang, Q., Davis, J.C., Lamborn, I.T., Freeman, A.F., Jing, H., Favreau, A.J., et al. Combined immunodeficiency associated with DOCK8 mutations. N. Engl. J. Med. 361 (2009), 2046–2055.
62. [62] Engelhardt, K.R., McGhee, S., Winkler, S., Sassi, A., Woellner, C., Lopez-Herrera, G., et al. Large deletions and point mutations involving the dedicator of cytokinesis 8 (DOCK8) in the autosomal-recessive form of hyper-IgE syndrome. J. Allergy Clin. Immunol. 124 (2009), 1289–1302 (e4).
63. [63] Holland, S.M., DeLeo, F.R., Elloumi, H.Z., Hsu, A.P., Uzel, G., Brodsky, N., et al. STAT3 mutations in the hyper-IgE syndrome. N. Engl. J. Med. 357 (2007), 1608–1619.
64. [64] Minegishi, Y., Saito, M., Tsuchiya, S., Tsuge, I., Takada, H., Hara, T., et al. Dominant-negative mutations in the DNA-binding domain of STAT3 cause hyper-IgE syndrome. Nature 448 (2007), 1058–1062.
65. [65] Freeman, A.F., Holland, S.M., The hyper-IgE syndromes. Immunol. Allergy Clin. North Am. 28 (2008), 277–291 (viii).
66. [66] Freeman, A.F., Domingo, D.L., Holland, S.M., Hyper IgE (Job's) syndrome: a primary immune deficiency with oral manifestations. Oral Dis. 15 (2009), 2–7.
67. [67] Minegishi, Y., Hyper-IgE syndrome. Curr. Opin. Immunol. 21 (2009), 487–492.
68. [68] Minegishi, Y., Karasuyama, H., Defects in Jak-STAT-mediated cytokine signals cause hyper-IgE syndrome: lessons from a primary immunodeficiency. Int. Immunol. 21 (2009), 105–112.
69. [69] Takeda, K., Clausen, B.E., Kaisho, T., Tsujimura, T., Terada, N., Forster, I., et al. Enhanced Th1 activity and development of chronic enterocolitis in mice devoid of Stat3 in macrophages and neutrophils. Immunity 10 (1999), 39–49.
70. [70] Takeda, K., Kaisho, T., Yoshida, N., Takeda, J., Kishimoto, T., Akira, S., Stat3 activation is responsible for IL-6-dependent T cell proliferation through preventing apoptosis: generation and characterization of T cell-specific Stat3-deficient mice. J. Immunol. 161 (1998), 4652–4660.
71. [71] Minegishi, Y., Saito, M., Nagasawa, M., Takada, H., Hara, T., Tsuchiya, S., et al. Molecular explanation for the contradiction between systemic Th17 defect and localized bacterial infection in hyper-IgE syndrome. J. Exp. Med. 206 (2009), 1291–1301.
72. [72] Steward-Tharp, S.M., Laurence, A., Kanno, Y., Kotlyar, A., Villarino, A.V., Sciume, G., et al. A mouse model of HIES reveals pro- and anti-inflammatory functions of STAT3. Blood 123 (2014), 2978–2987.
73. [73] Barrett, J.C., Hansoul, S., Nicolae, D.L., Cho, J.H., Duerr, R.H., Rioux, J.D., et al. Genome-wide association defines more than 30 distinct susceptibility loci for Crohn's disease. Nat. Genet. 40 (2008), 955–962.
74. [74] Cho, J.H., The genetics and immunopathogenesis of inflammatory bowel disease. Nat. Rev. Immunol. 8 (2008), 458–466.
75. [75] Jakkula, E., Leppa, V., Sulonen, A.M., Varilo, T., Kallio, S., Kemppinen, A., et al. Genome-wide association study in a high-risk isolate for multiple sclerosis reveals associated variants in STAT3 gene. Am. J. Hum. Genet. 86 (2010), 285–291.
76. [76] Tsoi, L.C., Spain, S.L., Knight, J., Ellinghaus, E., Stuart, P.E., Capon, F., et al. Identification of 15 new psoriasis susceptibility loci highlights the role of innate immunity. Nat. Genet. 44 (2012), 1341–1348.
77. [77] Flanagan, S.E., Haapaniemi, E., Russell, M.A., Caswell, R., Lango Allen, H., De Franco, E., et al. Activating germline mutations in STAT3 cause early-onset multi-organ autoimmune disease. Nat Genet. 46 (2014), 812–814.
78. [78] Haapaniemi, E.M., Kaustio, M., Rajala, H.L., van Adrichem, A.J., Kainulainen, L., Glumoff, V., et al. Autoimmunity, hypogammaglobulinemia, lymphoproliferation, and mycobacterial disease in patients with activating mutations in STAT3. Blood 125 (2015), 639–648.
79. [79] Milner, J.D., Vogel, T.P., Forbes, L., Ma, C.A., Stray-Pedersen, A., Niemela, J.E., et al. Early-onset lymphoproliferation and autoimmunity caused by germline STAT3 gain-of-function mutations. Blood 125 (2015), 591–599.
80. [80] Vogel, T.P., Milner, J.D., Cooper, M.A., The Ying and Yang of STAT3 in human disease. J. Clin. Immunol. 35 (2015), 615–623.
81. [81] Yao, Z., Kanno, Y., Kerenyi, M., Stephens, G., Durant, L., Watford, W.T., et al. Nonredundant roles for Stat5a/b in directly regulating Foxp3. Blood 109 (2007), 4368–4375.
82. [82] Xu, L., Kitani, A., Stuelten, C., McGrady, G., Fuss, I., Strober, W., Positive and negative transcriptional regulation of the Foxp3 gene is mediated by access and binding of the Smad3 protein to enhancer I. Immunity 33 (2010), 313–325.
83. [83] Laurence, A., Amarnath, S., Mariotti, J., Kim, Y.C., Foley, J., Eckhaus, M., et al. STAT3 transcription factor promotes instability of nTreg cells and limits generation of iTreg cells during acute murine graft-versus-host disease. Immunity 37 (2012), 209–222.
84. [84] Brunkow, M.E., Jeffery, E.W., Hjerrild, K.A., Paeper, B., Clark, L.B., Yasayko, S.A., et al. Disruption of a new forkhead/winged-helix protein, scurfin, results in the fatal lymphoproliferative disorder of the scurfy mouse. Nat. Genet. 27 (2001), 68–73.
85. [85] Fontenot, J.D., Gavin, M.A., Rudensky, A.Y., Foxp3 programs the development and function of CD4 + CD25+ regulatory T cells. Nat. Immunol. 4 (2003), 330–336.
86. [86] Kim, J.M., Rasmussen, J.P., Rudensky, A.Y., Regulatory T cells prevent catastrophic autoimmunity throughout the lifespan of mice. Nat. Immunol. 8 (2007), 191–197.
87. [87] Lahl, K., Loddenkemper, C., Drouin, C., Freyer, J., Arnason, J., Eberl, G., et al. Selective depletion of Foxp3+ regulatory T cells induces a scurfy-like disease. J. Exp. Med. 204 (2007), 57–63.
88. [88] Kim, J., Lahl, K., Hori, S., Loddenkemper, C., Chaudhry, A., deRoos, P., et al. Cutting edge: depletion of Foxp3+ cells leads to induction of autoimmunity by specific ablation of regulatory T cells in genetically targeted mice. J. Immunol. 183 (2009), 7631–7634.
89. [89] Takeda, K., Noguchi, K., Shi, W., Tanaka, T., Matsumoto, M., Yoshida, N., et al. Targeted disruption of the mouse Stat3 gene leads to early embryonic lethality. Proc. Natl. Acad. Sci. U. S. A. 94 (1997), 3801–3804.
90. [90] Raz, R., Lee, C.K., Cannizzaro, L.A., d'Eustachio, P., Levy, D.E., Essential role of STAT3 for embryonic stem cell pluripotency. Proc. Natl. Acad. Sci. U. S. A. 96 (1999), 2846–2851.
91. [91] Lee, C.K., Raz, R., Gimeno, R., Gertner, R., Wistinghausen, B., Takeshita, K., et al. STAT3 is a negative regulator of granulopoiesis but is not required for G-CSF-dependent differentiation. Immunity 17 (2002), 63–72.
92. [92] Welte, T., Zhang, S.S., Wang, T., Zhang, Z., Hesslein, D.G., Yin, Z., et al. STAT3 deletion during hematopoiesis causes Crohn's disease-like pathogenesis and lethality: a critical role of STAT3 in innate immunity. Proc. Natl. Acad. Sci. U. S. A. 100 (2003), 1879–1884.
93. [93] Alonzi, T., Newton, I.P., Bryce, P.J., Di Carlo, E., Lattanzio, G., Tripodi, M., et al. Induced somatic inactivation of STAT3 in mice triggers the development of a fulminant form of enterocolitis. Cytokine 26 (2004), 45–56.
94. [94] Panopoulos, A.D., Zhang, L., Snow, J.W., Jones, D.M., Smith, A.M., El Kasmi, K.C., et al. STAT3 governs distinct pathways in emergency granulopoiesis and mature neutrophils. Blood 108 (2006), 3682–3690.
95. [95] Akira, S., Roles of STAT3 defined by tissue-specific gene targeting. Oncogene 19 (2000), 2607–2611.
96. [96] Manz, M.G., Boettcher, S., Emergency granulopoiesis. Nat. Rev. Immunol. 14 (2014), 302–314.
97. [97] Cheers, C., Haigh, A.M., Kelso, A., Metcalf, D., Stanley, E.R., Young, A.M., Production of colony-stimulating factors (CSFs) during infection: separate determinations of macrophage-, granulocyte-, granulocyte-macrophage-, and multi-CSFs. Infect. Immun. 56 (1988), 247–251.
98. [98] Lieschke, G.J., Grail, D., Hodgson, G., Metcalf, D., Stanley, E., Cheers, C., et al. Mice lacking granulocyte colony-stimulating factor have chronic neutropenia, granulocyte and macrophage progenitor cell deficiency, and impaired neutrophil mobilization. Blood 84 (1994), 1737–1746.
99. [99] Boettcher, S., Gerosa, R.C., Radpour, R., Bauer, J., Ampenberger, F., Heikenwalder, M., et al. Endothelial cells translate pathogen signals into G-CSF-driven emergency granulopoiesis. Blood 124 (2014), 1393–1403.
100. [100] Panopoulos, A.D., Watowich, S.S., Granulocyte colony-stimulating factor: molecular mechanisms of action during steady state and ‘emergency’ hematopoiesis. Cytokine 42 (2008), 277–288.
101. [101] McLemore, M.L., Grewal, S., Liu, F., Archambault, A., Poursine-Laurent, J., Haug, J., et al. STAT-3 activation is required for normal G-CSF-dependent proliferation and granulocytic differentiation. Immunity 14 (2001), 193–204.
102. [102] Laouar, Y., Welte, T., Fu, X.Y., Flavell, R.A., STAT3 is required for Flt3L-dependent dendritic cell differentiation. Immunity 19 (2003), 903–912.
103. [103] Zhang, H., Nguyen-Jackson, H., Panopoulos, A.D., Li, H.S., Murray, P.J., Watowich, S.S., STAT3 controls myeloid progenitor growth during emergency granulopoiesis. Blood 116 (2010), 2462–2471.
104. [104] Nguyen-Jackson, H., Panopoulos, A.D., Zhang, H., Li, H.S., Watowich, S.S., STAT3 controls the neutrophil migratory response to CXCR2 ligands by direct activation of G-CSF-induced CXCR2 expression and via modulation of CXCR2 signal transduction. Blood 115 (2010), 3354–3363.
105. [105] Mantel, C., Messina-Graham, S., Moh, A., Cooper, S., Hangoc, G., Fu, X.Y., et al. Mouse hematopoietic cell-targeted STAT3 deletion: stem/progenitor cell defects, mitochondrial dysfunction, ROS overproduction, and a rapid aging-like phenotype. Blood 120 (2012), 2589–2599.
106. [106] Li, H.S., Yang, C.Y., Nallaparaju, K.C., Zhang, H., Liu, Y.J., Goldrath, A.W., et al. The signal transducers STAT5 and STAT3 control expression of Id2 and E2-2 during dendritic cell development. Blood 120 (2012), 4363–4373.
107. [107] Johansen, L.M., Iwama, A., Lodie, T.A., Sasaki, K., Felsher, D.W., Golub, T.R., et al. c-Myc is a critical target for c/EBPalpha in granulopoiesis. Mol. Cell. Biol. 21 (2001), 3789–3806.
108. [108] Hirai, H., Zhang, P., Dayaram, T., Hetherington, C.J., Mizuno, S., Imanishi, J., et al. C/EBPbeta is required for ‘emergency’ granulopoiesis. Nat. Immunol. 7 (2006), 732–739.
109. [109] Nguyen-Jackson, H.T., Li, H.S., Zhang, H., Ohashi, E., Watowich, S.S., G-CSF-activated STAT3 enhances production of the chemokine MIP-2 in bone marrow neutrophils. J. Leukoc. Biol. 92 (2012), 1215–1225.
110. [110] Fielding, C.A., McLoughlin, R.M., McLeod, L., Colmont, C.S., Najdovska, M., Grail, D., et al. IL-6 regulates neutrophil trafficking during acute inflammation via STAT3. J. Immunol. 181 (2008), 2189–2195.
111. [111] Croker, B.A., Metcalf, D., Robb, L., Wei, W., Mifsud, S., DiRago, L., et al. SOCS3 is a critical physiological negative regulator of G-CSF signaling and emergency granulopoiesis. Immunity 20 (2004), 153–165.
112. [112] Wormald, S., Hilton, D.J., Inhibitors of cytokine signal transduction. J. Biol. Chem. 279 (2004), 821–824.
113. [113] Murray, P.J., The JAK-STAT signaling pathway: input and output integration. J. Immunol. 178 (2007), 2623–2629.
114. [114] Auernhammer, C.J., Bousquet, C., Melmed, S., Autoregulation of pituitary corticotroph SOCS-3 expression: characterization of the murine SOCS-3 promoter. Proc. Natl. Acad. Sci. U. S. A. 96 (1999), 6964–6969.
115. [115] Babon, J.J., Kershaw, N.J., Murphy, J.M., Varghese, L.N., Laktyushin, A., Young, S.N., et al. Suppression of cytokine signaling by SOCS3: characterization of the mode of inhibition and the basis of its specificity. Immunity 36 (2012), 239–250.
116. [116] Kershaw, N.J., Murphy, J.M., Liau, N.P., Varghese, L.N., Laktyushin, A., Whitlock, E.L., et al. SOCS3 binds specific receptor-JAK complexes to control cytokine signaling by direct kinase inhibition. Nat. Struct. Mol. Biol. 20 (2013), 469–476.
117. [117] Croker, B.A., Mielke, L.A., Wormald, S., Metcalf, D., Kiu, H., Alexander, W.S., et al. Socs3 maintains the specificity of biological responses to cytokine signals during granulocyte and macrophage differentiation. Exp. Hematol. 36 (2008), 786–798.
118. [118] Matsukawa, A., Takeda, K., Kudo, S., Maeda, T., Kagayama, M., Akira, S., Aberrant inflammation and lethality to septic peritonitis in mice lacking STAT3 in macrophages and neutrophils. J. Immunol. 171 (2003), 6198–6205.
119. [119] Hill, H.R., Quie, P.G., Raised serum-IgE levels and defective neutrophil chemotaxis in three children with eczema and recurrent bacterial infections. Lancet 1 (1974), 183–187.
120. [120] Hill, H.R., Ochs, H.D., Quie, P.G., Clark, R.A., Pabst, H.F., Klebanoff, S.J., et al. Defect in neutrophil granulocyte chemotaxis in Job's syndrome of recurrent cold staphylococcal abscesses. Lancet 2 (1974), 617–619.
121. [121] Mintz, R., Garty, B.Z., Meshel, T., Marcus, N., Katanov, C., Cohen-Hillel, E., et al. Reduced expression of chemoattractant receptors by polymorphonuclear leukocytes in Hyper IgE Syndrome patients. Immunol. Lett. 130 (2010), 97–106.
122. [122] Mogensen, T.H., STAT3 and the Hyper-IgE syndrome: clinical presentation, genetic origin, pathogenesis, novel findings and remaining uncertainties. Jakstat, 2, 2013, e23435.
123. [123] Liu, F., Poursine-Laurent, J., Wu, H.Y., Link, D.C., Interleukin-6 and the granulocyte colony-stimulating factor receptor are major independent regulators of granulopoiesis in vivo but are not required for lineage commitment or terminal differentiation. Blood 90 (1997), 2583–2590.
124. [124] Liu, F., Wu, H.Y., Wesselschmidt, R., Kornaga, T., Link, D.C., Impaired production and increased apoptosis of neutrophils in granulocyte colony-stimulating factor receptor-deficient mice. Immunity 5 (1996), 491–501.
125. [125] Richards, M.K., Liu, F., Iwasaki, H., Akashi, K., Link, D.C., Pivotal role of granulocyte colony-stimulating factor in the development of progenitors in the common myeloid pathway. Blood 102 (2003), 3562–3568.
126. [126] Semerad, C.L., Poursine-Laurent, J., Liu, F., Link, D.C., A role for G-CSF receptor signaling in the regulation of hematopoietic cell function but not lineage commitment or differentiation. Immunity 11 (1999), 153–161.
127. [127] Panopoulos, A.D., Bartos, D., Zhang, L., Watowich, S.S., Control of myeloid-specific integrin alpha Mbeta 2 (CD11b/CD18) expression by cytokines is regulated by Stat3-dependent activation of PU.1. J. Biol. Chem. 277 (2002), 19001–19007.
128. [128] MacNamara, K.C., Oduro, K., Martin, O., Jones, D.D., McLaughlin, M., Choi, K., et al. Infection-induced myelopoiesis during intracellular bacterial infection is critically dependent upon IFN-gamma signaling. J. Immunol. 186 (2011), 1032–1043.
129. [129] de Bruin, A.M., Libregts, S.F., Valkhof, M., Boon, L., Touw, I.P., Nolte, M.A., IFNgamma induces monopoiesis and inhibits neutrophil development during inflammation. Blood 119 (2012), 1543–1554.
130. [130] Jouanguy, E., Doffinger, R., Dupuis, S., Pallier, A., Altare, F., Casanova, J.L., IL-12 and IFN-gamma in host defense against mycobacteria and salmonella in mice and men. Curr. Opin. Immunol. 11 (1999), 346–351.
131. [131] Gardner, J.C., Noel, J.G., Nikolaidis, N.M., Karns, R., Aronow, B.J., Ogle, C.K., et al. G-CSF drives a posttraumatic immune program that protects the host from infection. J. Immunol. 192 (2014), 2405–2417.
132. [132] Merad, M., Manz, M.G., Dendritic cell homeostasis. Blood 113 (2009), 3418–3427.
133. [133] Merad, M., Sathe, P., Helft, J., Miller, J., Mortha, A., The dendritic cell lineage: ontogeny and function of dendritic cells and their subsets in the steady state and the inflamed setting. Annu. Rev. Immunol. 31 (2013), 563–604.
134. [134] McKenna, H.J., Stocking, K.L., Miller, R.E., Brasel, K., De Smedt, T., Maraskovsky, E., et al. Mice lacking flt3 ligand have deficient hematopoiesis affecting hematopoietic progenitor cells, dendritic cells, and natural killer cells. Blood 95 (2000), 3489–3497.
135. [135] Esashi, E., Wang, Y.H., Perng, O., Qin, X.F., Liu, Y.J., Watowich, S.S., The signal transducer STAT5 inhibits plasmacytoid dendritic cell development by suppressing transcription factor IRF8. Immunity 28 (2008), 509–520.
136. [136] Singh, P., Hoggatt, J., Hu, P., Speth, J.M., Fukuda, S., Breyer, R.M., et al. Blockade of prostaglandin E2 signaling through EP1 and EP3 receptors attenuates Flt3L-dependent dendritic cell development from hematopoietic progenitor cells. Blood 119 (2012), 1671–1682.
137. [137] D'Amico, A., Wu, L., The early progenitors of mouse dendritic cells and plasmacytoid predendritic cells are within the bone marrow hemopoietic precursors expressing Flt3. J. Exp. Med. 198 (2003), 293–303.
138. [138] Onai, N., Obata-Onai, A., Tussiwand, R., Lanzavecchia, A., Manz, M.G., Activation of the Flt3 signal transduction cascade rescues and enhances type I interferon-producing and dendritic cell development. J. Exp. Med. 203 (2006), 227–238.
139. [139] Hegde, S., Ni, S., He, S., Yoon, D., Feng, G.S., Watowich, S.S., et al. Stat3 promotes the development of erythroleukemia by inducing Pu: 1 expression and inhibiting erythroid differentiation. Oncogene 28 (2009), 3349–3359.
140. [140] Carotta, S., Dakic, A., D'Amico, A., Pang, S.H.M., Greig, K.T., Nutt, S.L., et al. The transcription factor PU.1 controls dendritic cell development and Flt3 cytokine receptor expression in a dose-dependent manner. Immunity. 32 (2010), 628–641.
141. [141] Watowich, S.S., Liu, Y.J., Mechanisms regulating dendritic cell specification and development. Immunol. Rev. 238 (2010), 76–92.
142. [142] Melillo, J.A., Song, L., Bhagat, G., Blazquez, A.B., Plumlee, C.R., Lee, C., et al. Dendritic cell (DC)-specific targeting reveals Stat3 as a negative regulator of DC function. J. Immunol. 184 (2010), 2638–2645.
143. [143] Cisse, B., Caton, M.L., Lehner, M., Maeda, T., Scheu, S., Locksley, R., et al. Transcription factor E2-2 is an essential and specific regulator of plasmacytoid dendritic cell development. Cell 135 (2008), 37–48.
144. [144] Hacker, C., Kirsch, R.D., Ju, X.S., Hieronymus, T., Gust, T.C., Kuhl, C., et al. Transcriptional profiling identifies Id2 function in dendritic cell development. Nat. Immunol. 4 (2003), 380–386.
145. [145] Kee, B.L., E and ID proteins branch out. Nat. Rev. Immunol. 9 (2009), 175–184.
146. [146] Li, H.S., Watowich, S.S., Diversification of dendritic cell subsets: emerging roles for STAT proteins. JAKSTAT, 2, 2013, e25112.
147. [147] Cheng, F., Wang, H.W., Cuenca, A., Huang, M., Ghansah, T., Brayer, J., et al. A critical role for Stat3 signaling in immune tolerance. Immunity 19 (2003), 425–436.
148. [148] Wang, T., Niu, G., Kortylewski, M., Burdelya, L., Shain, K., Zhang, S., et al. Regulation of the innate and adaptive immune responses by Stat-3 signaling in tumor cells. Nat. Med. 10 (2004), 48–54.
149. [149] Nefedova, Y., Huang, M., Kusmartsev, S., Bhattacharya, R., Cheng, P., Salup, R., et al. Hyperactivation of STAT3 is involved in abnormal differentiation of dendritic cells in cancer. J. Immunol. 172 (2004), 464–474.
150. [150] Lunz, J.G. 3rd., Specht, S.M., Murase, N., Isse, K., Demetris, A.J., Gut-derived commensal bacterial products inhibit liver dendritic cell maturation by stimulating hepatic interleukin-6/signal transducer and activator of transcription 3 activity. Hepatology 46 (2007), 1946–1959.
151. [151] Lin, A., Schildknecht, A., Nguyen, L.T., Ohashi, P.S., Dendritic cells integrate signals from the tumor microenvironment to modulate immunity and tumor growth. Immunol. Lett. 127 (2010), 77–84.
152. [152] Park, S.J., Nakagawa, T., Kitamura, H., Atsumi, T., Kamon, H., Sawa, S., et al. IL-6 regulates in vivo dendritic cell differentiation through STAT3 activation. J. Immunol. 173 (2004), 3844–3854.
153. [153] Kitamura, H., Kamon, H., Sawa, S., Park, S.J., Katunuma, N., Ishihara, K., et al. IL-6-STAT3 controls intracellular MHC class II alphabeta dimer level through cathepsin S activity in dendritic cells. Immunity 23 (2005), 491–502.
154. [154] Cheng, P., Corzo, C.A., Luetteke, N., Yu, B., Nagaraj, S., Bui, M.M., et al. Inhibition of dendritic cell differentiation and accumulation of myeloid-derived suppressor cells in cancer is regulated by S100A9 protein. J. Exp. Med. 205 (2008), 2235–2249.
155. [155] Wolfle, S.J., Strebovsky, J., Bartz, H., Sahr, A., Arnold, C., Kaiser, C., et al. PD-L1 expression on tolerogenic APCs is controlled by STAT-3. Eur. J. Immunol. 41 (2011), 413–424.
156. [156] Corinti, S., Albanesi, C., la Sala, A., Pastore, S., Girolomoni, G., Regulatory activity of autocrine IL-10 on dendritic cell functions. J. Immunol. 166 (2001), 4312–4318.
157. [157] Liang, S., Ristich, V., Arase, H., Dausset, J., Carosella, E.D., Horuzsko, A., Modulation of dendritic cell differentiation by HLA-G and ILT4 requires the IL-6–STAT3 signaling pathway. Proc. Natl. Acad. Sci. U. S. A. 105 (2008), 8357–8362.
158. [158] Nefedova, Y., Nagaraj, S., Rosenbauer, A., Muro-Cacho, C., Sebti, S.M., Gabrilovich, D.I., Regulation of dendritic cell differentiation and antitumor immune response in cancer by pharmacologic-selective inhibition of the janus-activated kinase 2/signal transducers and activators of transcription 3 pathway. Cancer Res. 65 (2005), 9525–9535.
159. [159] Bharadwaj, U., Li, M., Zhang, R., Chen, C., Yao, Q., Elevated interleukin-6 and G-CSF in human pancreatic cancer cell conditioned medium suppress dendritic cell differentiation and activation. Cancer Res. 67 (2007), 5479–5488.
160. [160] Sanseverino, I., Purificato, C., Varano, B., Conti, L., Gessani, S., Gauzzi, M.C., STAT3-silenced human dendritic cells have an enhanced ability to prime IFNgamma production by both alphabeta and gammadelta T lymphocytes. Immunobiology 219 (2014), 503–511.
161. [161] Kobayashi, M., Kweon, M.N., Kuwata, H., Schreiber, R.D., Kiyono, H., Takeda, K., et al. Toll-like receptor-dependent production of IL-12p40 causes chronic enterocolitis in myeloid cell-specific Stat3-deficient mice. J. Clin. Invest. 111 (2003), 1297–1308.
162. [162] Reindl, W., Weiss, S., Lehr, H.A., Forster, I., Essential crosstalk between myeloid and lymphoid cells for development of chronic colitis in myeloid-specific signal transducer and activator of transcription 3-deficient mice. Immunology 120 (2007), 19–27.
163. [163] Kuhn, R., Lohler, J., Rennick, D., Rajewsky, K., Muller, W., Interleukin-10-deficient mice develop chronic enterocolitis. Cell 75 (1993), 263–274.
164. [164] Hoshi, N., Schenten, D., Nish, S.A., Walther, Z., Gagliani, N., Flavell, R.A., et al. MyD88 signalling in colonic mononuclear phagocytes drives colitis in IL-10-deficient mice. Nat. Commun., 3, 2012, 1120.
165. [165] Lang, R., Patel, D., Morris, J.J., Rutschman, R.L., Murray, P.J., Shaping gene expression in activated and resting primary macrophages by IL-10. J. Immunol. 169 (2002), 2253–2263.
166. [166] Williams, L., Bradley, L., Smith, A., Foxwell, B., Signal transducer and activator of transcription 3 is the dominant mediator of the anti-inflammatory effects of IL-10 in human macrophages. J. Immunol. 172 (2004), 567–576.
167. [167] El Kasmi, K.C., Holst, J., Coffre, M., Mielke, L., de Pauw, A., Lhocine, N., et al. General nature of the STAT3-activated anti-inflammatory response. J. Immunol. 177 (2006), 7880–7888.
168. [168] Williams, L.M., Sarma, U., Willets, K., Smallie, T., Brennan, F., Foxwell, B.M., Expression of constitutively active STAT3 can replicate the cytokine-suppressive activity of interleukin-10 in human primary macrophages. J. Biol. Chem. 282 (2007), 6965–6975.
169. [169] Murray, P.J., The primary mechanism of the IL-10-regulated antiinflammatory response is to selectively inhibit transcription. Proc. Natl. Acad. Sci. U. S. A. 102 (2005), 8686–8691.
170. [170] El Kasmi, K.C., Smith, A.M., Williams, L., Neale, G., Panopoulos, A.D., Watowich, S.S., et al. Cutting edge: a transcriptional repressor and corepressor induced by the STAT3-regulated anti-inflammatory signaling pathway. J. Immunol. 179 (2007), 7215–7219.
171. [171] Schaljo, B., Kratochvill, F., Gratz, N., Sadzak, I., Sauer, I., Hammer, M., et al. Tristetraprolin is required for full anti-inflammatory response of murine macrophages to IL-10. J. Immunol. 183 (2009), 1197–1206.
172. [172] Chan, C.S., Ming-Lum, A., Golds, G.B., Lee, S.J., Anderson, R.J., Mui, A.L., Interleukin-10 inhibits lipopolysaccharide-induced tumor necrosis factor-alpha translation through a SHIP1-dependent pathway. J. Biol. Chem. 287 (2012), 38020–38027.
173. [173] Gaba, A., Grivennikov, S.I., Do, M.V., Stumpo, D.J., Blackshear, P.J., Karin, M., Cutting edge: IL-10-mediated tristetraprolin induction is part of a feedback loop that controls macrophage STAT3 activation and cytokine production. J. Immunol. 189 (2012), 2089–2093.
174. [174] Smith, A.M., Qualls, J.E., O'Brien, K., Balouzian, L., Johnson, P.F., Schultz-Cherry, S., et al. A distal enhancer in Il12b is the target of transcriptional repression by the STAT3 pathway and requires the basic leucine zipper (B-ZIP) protein NFIL3. J. Biol. Chem. 286 (2011), 23582–23590.
175. [175] Hutchins, A.P., Poulain, S., Miranda-Saavedra, D., Genome-wide analysis of STAT3 binding in vivo predicts effectors of the anti-inflammatory response in macrophages. Blood 119 (2012), e110–9.
176. [176] Curtale, G., Mirolo, M., Renzi, T.A., Rossato, M., Bazzoni, F., Locati, M., Negative regulation of Toll-like receptor 4 signaling by IL-10-dependent microRNA-146b. Proc. Natl. Acad. Sci. U. S. A. 110 (2013), 11499–11504.
177. [177] Hutchins, A.P., Diez, D., Miranda-Saavedra, D., The IL-10/STAT3-mediated anti-inflammatory response: recent developments and future challenges. Brief Funct. Genomics 12 (2013), 489–498.
178. [178] Zhang, H., Hu, H., Greeley, N., Jin, J., Matthews, A.J., Ohashi, E., et al. STAT3 restrains RANK- and TLR4-mediated signalling by suppressing expression of the E2 ubiquitin-conjugating enzyme Ubc13. Nat. Commun., 5, 2014, 5798.
179. [179] Yasukawa, H., Ohishi, M., Mori, H., Murakami, M., Chinen, T., Aki, D., et al. IL-6 induces an anti-inflammatory response in the absence of SOCS3 in macrophages. Nat. Immunol. 4 (2003), 551–556.
180. [180] Johnston, J.A., O'Shea, J.J., Matching SOCS with function. Nat. Immunol. 4 (2003), 507–509.
181. [181] Heimall, J., Freeman, A., Holland, S.M., Pathogenesis of hyper IgE syndrome. Clin. Rev. Allergy Immunol. 38 (2010), 32–38.
182. [182] Saito, M., Nagasawa, M., Takada, H., Hara, T., Tsuchiya, S., Agematsu, K., et al. Defective IL-10 signaling in hyper-IgE syndrome results in impaired generation of tolerogenic dendritic cells and induced regulatory T cells. J. Exp. Med. 208 (2011), 235–249.
183. [183] Sowerwine, K.J., Shaw, P.A., Gu, W., Ling, J.C., Collins, M.T., Darnell, D.N., et al. Bone density and fractures in autosomal dominant hyper IgE syndrome. J. Clin. Immunol. 34 (2014), 260–264.
184. [184] Kano, A., Wolfgang, M.J., Gao, Q., Jacoby, J., Chai, G.X., Hansen, W., et al. Endothelial cells require STAT3 for protection against endotoxin-induced inflammation. J. Exp. Med. 198 (2003), 1517–1525.
185. [185] Burdelya, L., Kujawski, M., Niu, G., Zhong, B., Wang, T., Zhang, S., et al. Stat3 activity in melanoma cells affects migration of immune effector cells and nitric oxide-mediated antitumor effects. J. Immunol. 174 (2005), 3925–3931.
186. [186] Sugimoto, K., Ogawa, A., Mizoguchi, E., Shimomura, Y., Andoh, A., Bhan, A.K., et al. IL-22 ameliorates intestinal inflammation in a mouse model of ulcerative colitis. J. Clin. Invest. 118 (2008), 534–544.
187. [187] Pickert, G., Neufert, C., Leppkes, M., Zheng, Y., Wittkopf, N., Warntjen, M., et al. STAT3 links IL-22 signaling in intestinal epithelial cells to mucosal wound healing. J. Exp. Med. 206 (2009), 1465–1472.
188. [188] Takatori, H., Kanno, Y., Watford, W.T., Tato, C.M., Weiss, G., Ivanov, I.I., et al. Lymphoid tissue inducer-like cells are an innate source of IL-17 and IL-22. J. Exp. Med. 206 (2009), 35–41.
189. [189] Chou, W.C., Levy, D.E., Lee, C.K., STAT3 positively regulates an early step in B-cell development. Blood 108 (2006), 3005–3011.
190. [190] Fornek, J.L., Tygrett, L.T., Waldschmidt, T.J., Poli, V., Rickert, R.C., Kansas, G.S., Critical role for Stat3 in T-dependent terminal differentiation of IgG B cells. Blood 107 (2006), 1085–1091.
191. [191] Leonard, W.J., Zeng, R., Spolski, R., Interleukin 21: a cytokine/cytokine receptor system that has come of age. J. Leukoc. Biol. 84 (2008), 348–356.
192. [192] Diehl, S.A., Schmidlin, H., Nagasawa, M., Blom, B., Spits, H., IL-6 triggers IL-21 production by human CD4+ T cells to drive STAT3-dependent plasma cell differentiation in B cells. Immunol. Cell Biol. 90 (2012), 802–811.
193. [193] Ding, B.B., Bi, E., Chen, H., Yu, J.J., Ye, B.H., IL-21 and CD40L synergistically promote plasma cell differentiation through upregulation of Blimp-1 in human B cells. J. Immunol. 190 (2013), 1827–1836.
194. [194] Hunter, C.A., Jones, S.A., IL-6 as a keystone cytokine in health and disease. Nat. Immunol. 16 (2015), 448–457.
195. [195] Wang, R.X., Yu, C.R., Dambuza, I.M., Mahdi, R.M., Dolinska, M.B., Sergeev, Y.V., et al. Interleukin-35 induces regulatory B cells that suppress autoimmune disease. Nat. Med. 20 (2014), 633–641.
196. [196] Speckmann, C., Enders, A., Woellner, C., Thiel, D., Rensing-Ehl, A., Schlesier, M., et al. Reduced memory B cells in patients with hyper IgE syndrome. Clin. Immunol. 129 (2008), 448–454.
197. [197] Avery, D.T., Deenick, E.K., Ma, C.S., Suryani, S., Simpson, N., Chew, G.Y., et al. B cell-intrinsic signaling through IL-21 receptor and STAT3 is required for establishing long-lived antibody responses in humans. J. Exp. Med. 207 (2010), 155–171.
198. [198] Ma, C.S., Avery, D.T., Chan, A., Batten, M., Bustamante, J., Boisson-Dupuis, S., et al. Functional STAT3 deficiency compromises the generation of human T follicular helper cells. Blood 119 (2012), 3997–4008.
199. [199] Ma, C.S., Wong, N., Rao, G., Avery, D.T., Torpy, J., Hambridge, T., et al. Monogenic mutations differentially affect the quantity and quality of T follicular helper cells in patients with human primary immunodeficiencies. J. Allergy Clin. Immunol. 136 (2015), 993–1006 (e1).
200. [200] Kanno, Y., Vahedi, G., Hirahara, K., Singleton, K., O'Shea, J.J., Transcriptional and epigenetic control of T helper cell specification: molecular mechanisms underlying commitment and plasticity. Annu. Rev. Immunol. 30 (2012), 707–731.
201. [201] Liu, X., Lee, Y.S., Yu, C.R., Egwuagu, C.E., Loss of STAT3 in CD4+ T cells prevents development of experimental autoimmune diseases. J. Immunol. 180 (2008), 6070–6076.
202. [202] Laurence, A., Tato, C.M., Davidson, T.S., Kanno, Y., Chen, Z., Yao, Z., et al. Interleukin-2 signaling via STAT5 constrains T helper 17 cell generation. Immunity 26 (2007), 371–381.
203. [203] Yang, X.O., Panopoulos, A.D., Nurieva, R., Chang, S.H., Wang, D., Watowich, S.S., et al. STAT3 regulates cytokine-mediated generation of inflammatory helper T cells. J. Biol. Chem. 282 (2007), 9358–9363.
204. [204] Zhou, L., Ivanov, I.I., Spolski, R., Min, R., Shenderov, K., Egawa, T., et al. IL-6 programs T(H)-17 cell differentiation by promoting sequential engagement of the IL-21 and IL-23 pathways. Nat. Immunol. 8 (2007), 967–974.
205. [205] Nurieva, R., Yang, X.O., Martinez, G., Zhang, Y., Panopoulos, A.D., Ma, L., et al. Essential autocrine regulation by IL-21 in the generation of inflammatory T cells. Nature 448 (2007), 480–483.
206. [206] Ivanov, I.I., McKenzie, B.S., Zhou, L., Tadokoro, C.E., Lepelley, A., Lafaille, J.J., et al. The orphan nuclear receptor RORgammat directs the differentiation program of proinflammatory IL-17+ T helper cells. Cell 126 (2006), 1121–1133.
207. [207] Yang, X.O., Pappu, B.P., Nurieva, R., Akimzhanov, A., Kang, H.S., Chung, Y., et al. T helper 17 lineage differentiation is programmed by orphan nuclear receptors ROR alpha and ROR gamma. Immunity 28 (2008), 29–39.
208. [208] Gaffen, S.L., Structure and signalling in the IL-17 receptor family. Nat. Rev. Immunol. 9 (2009), 556–567.
209. [209] Gaffen, S.L., Recent advances in the IL-17 cytokine family. Curr. Opin. Immunol. 23 (2011), 613–619.
210. [210] Nurieva, R.I., Chung, Y., Hwang, D., Yang, X.O., Kang, H.S., Ma, L., et al. Generation of T follicular helper cells is mediated by interleukin-21 but independent of T helper 1, 2, or 17 cell lineages. Immunity 29 (2008), 138–149.
211. [211] Liu, X., Yan, X., Zhong, B., Nurieva, R.I., Wang, A., Wang, X., et al. Bcl6 expression specifies the T follicular helper cell program in vivo. J. Exp. Med. 209 (2012), 1841–1852 s1–24.
212. [212] Batten, M., Ramamoorthi, N., Kljavin, N.M., Ma, C.S., Cox, J.H., Dengler, H.S., et al. IL-27 supports germinal center function by enhancing IL-21 production and the function of T follicular helper cells. J. Exp. Med. 207 (2010), 2895–2906.
213. [213] Yang, X.O., Nurieva, R., Martinez, G.J., Kang, H.S., Chung, Y., Pappu, B.P., et al. Molecular antagonism and plasticity of regulatory and inflammatory T cell programs. Immunity 29 (2008), 44–56.
214. [214] Chaudhry, A., Samstein, R.M., Treuting, P., Liang, Y., Pils, M.C., Heinrich, J.M., et al. Interleukin-10 signaling in regulatory T cells is required for suppression of Th17 cell-mediated inflammation. Immunity 34 (2011), 566–578.
215. [215] Chaudhry, A., Rudra, D., Treuting, P., Samstein, R.M., Liang, Y., Kas, A., et al. CD4+ regulatory T cells control TH17 responses in a Stat3-dependent manner. Science 326 (2009), 986–991.
216. [216] Chaudhry, A., Rudensky, A.Y., Control of inflammation by integration of environmental cues by regulatory T cells. J. Clin. Invest. 123 (2013), 939–944.
217. [217] Yang, X.P., Ghoreschi, K., Steward-Tharp, S.M., Rodriguez-Canales, J., Zhu, J., Grainger, J.R., et al. Opposing regulation of the locus encoding IL-17 through direct, reciprocal actions of STAT3 and STAT5. Nat. Immunol. 12 (2011), 247–254.
218. [218] Minegishi, Y., Saito, M., Molecular mechanisms of the immunological abnormalities in hyper-IgE syndrome. Ann. N. Y. Acad. Sci. 1246 (2011), 34–40.
219. [219] Cui, W., Liu, Y., Weinstein, J.S., Craft, J., Kaech, S.M., An interleukin-21-interleukin-10-STAT3 pathway is critical for functional maturation of memory CD8+ T cells. Immunity 35 (2011), 792–805.
220. [220] Kaech, S.M., Cui, W., Transcriptional control of effector and memory CD8+ T cell differentiation. Nat. Rev. Immunol. 12 (2012), 749–761.
221. [221] Laidlaw, B.J., Cui, W., Amezquita, R.A., Gray, S.M., Guan, T., Lu, Y., et al. Production of IL-10 by CD4(+) regulatory T cells during the resolution of infection promotes the maturation of memory CD8(+) T cells. Nat. Immunol. 16 (2015), 871–879.
222. [222] Siegel, A.M., Heimall, J., Freeman, A.F., Hsu, A.P., Brittain, E., Brenchley, J.M., et al. A critical role for STAT3 transcription factor signaling in the development and maintenance of human T cell memory. Immunity 35 (2011), 806–818.
223. [223] Ives, M.L., Ma, C.S., Palendira, U., Chan, A., Bustamante, J., Boisson-Dupuis, S., et al. Signal transducer and activator of transcription 3 (STAT3) mutations underlying autosomal dominant hyper-IgE syndrome impair human CD8(+) T-cell memory formation and function. J. Allergy Clin. Immunol. 132 (2013), 400–411 (e9).
224. [224] Siegel, A.M., Stone, K.D., Cruse, G., Lawrence, M.G., Olivera, A., Jung, M.Y., et al. Diminished allergic disease in patients with STAT3 mutations reveals a role for STAT3 signaling in mast cell degranulation. J. Allergy Clin. Immunol. 132 (2013), 1388–1396.
225. [225] Yan, B., Wei, J.J., Yuan, Y., Sun, R., Li, D., Luo, J., et al. IL-6 cooperates with G-CSF to induce protumor function of neutrophils in bone marrow by enhancing STAT3 activation. J. Immunol. 190 (2013), 5882–5893.